TaiMed Biologics (Taiwan) Performance
| 4147 Stock | TWD 99.30 0.40 0.40% |
On a scale of 0 to 100, TaiMed Biologics holds a performance score of 10. The entity has a beta of 0.3, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, TaiMed Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding TaiMed Biologics is expected to be smaller as well. Please check TaiMed Biologics' downside deviation, information ratio, and the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether TaiMed Biologics' existing price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in TaiMed Biologics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, TaiMed Biologics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 572.1 M | |
| Total Cashflows From Investing Activities | 190.9 M |
TaiMed |
TaiMed Biologics Relative Risk vs. Return Landscape
If you would invest 8,360 in TaiMed Biologics on November 27, 2024 and sell it today you would earn a total of 1,570 from holding TaiMed Biologics or generate 18.78% return on investment over 90 days. TaiMed Biologics is generating 0.338% of daily returns and assumes 2.4621% volatility on return distribution over the 90 days horizon. Simply put, 21% of stocks are less volatile than TaiMed, and 94% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
TaiMed Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TaiMed Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TaiMed Biologics, and traders can use it to determine the average amount a TaiMed Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1373
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 4147 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.46 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.34 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average TaiMed Biologics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TaiMed Biologics by adding it to a well-diversified portfolio.
TaiMed Biologics Fundamentals Growth
TaiMed Stock prices reflect investors' perceptions of the future prospects and financial health of TaiMed Biologics, and TaiMed Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TaiMed Stock performance.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.062 | |||
| Profit Margin | (1.70) % | |||
| Operating Margin | (1.47) % | |||
| Current Valuation | 17.73 B | |||
| Shares Outstanding | 252.37 M | |||
| Price To Book | 6.45 X | |||
| Price To Sales | 55.99 X | |||
| Revenue | 413.44 M | |||
| EBITDA | (306.83 M) | |||
| Cash And Equivalents | 1.02 B | |||
| Cash Per Share | 4.03 X | |||
| Total Debt | 536 M | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | 10.88 X | |||
| Cash Flow From Operations | (211.28 M) | |||
| Earnings Per Share | (2.36) X | |||
| Total Asset | 4.61 B | |||
About TaiMed Biologics Performance
Evaluating TaiMed Biologics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if TaiMed Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TaiMed Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company was founded in 2007 and is based in Taipei City, Taiwan. TAIMED BIOLOGICS operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about TaiMed Biologics performance evaluation
Checking the ongoing alerts about TaiMed Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TaiMed Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 413.44 M. Net Loss for the year was (470.93 M) with profit before overhead, payroll, taxes, and interest of 177.82 M. | |
| TaiMed Biologics has accumulated about 1.02 B in cash with (211.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03. | |
| Roughly 17.0% of the company shares are owned by insiders or employees |
- Analyzing TaiMed Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TaiMed Biologics' stock is overvalued or undervalued compared to its peers.
- Examining TaiMed Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TaiMed Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TaiMed Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TaiMed Biologics' stock. These opinions can provide insight into TaiMed Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.